Together, these findings suggest that CBD treatment markedly improves microglial phagocytic capacity via the TRPV2 channel and promotes Aβ clearance in microglia cells, further corroborating the role of CBD as a candidate drug for AD. Here, TRPV2 is linked to Alzheimer disease.